Download PDF
Thromb Haemost 2010; 104(06): 1272-1274
DOI: 10.1160/TH10-05-0313
Letters to the Editor
Schattauer GmbH

Fluoxetine inhibition of 5-HT-potentiated platelet aggregation in whole blood

Vasileios G. Bampalis
1   Institute for Prevention of Cardiovascular Diseases, Ludwig-Maximilians-University of Munich, Munich, Germany
,
Anna L. Khandoga
1   Institute for Prevention of Cardiovascular Diseases, Ludwig-Maximilians-University of Munich, Munich, Germany
,
Wolfgang Siess
1   Institute for Prevention of Cardiovascular Diseases, Ludwig-Maximilians-University of Munich, Munich, Germany
› Author Affiliations
Further Information

Publication History

Received: 21 May 2010

Accepted after minor revision: 21 July 2010

Publication Date:
24 November 2017 (online)

Also available at
    Permissions and Reprints

 

 

  • References

  • 1 de Abajo FJ, Montero D, Rodriguez LA. et al. Antidepressants and risk of upper gastrointestinal bleeding. Basic Clin Pharmacol Toxicol 2006; 98: 304-310.
    CrossrefPubMedGoogle Scholar
  • 2 Maurer-Spurej E, Pittendreigh C, Misri S. Platelet serotonin levels support depression scores for women with postpartum depression. J Psychiatry Neurosci 2007; 32: 23-29.
    PubMedGoogle Scholar
  • 3 Schlienger RG, Meier CR. Effect of selective serotonin reuptake inhibitors on platelet activation: can they prevent acute myocardial infarction?. Am J Cardiovasc Drugs 2003; 3: 149-162.
    CrossrefPubMedGoogle Scholar
  • 4 Maurer-Spurej E, Pittendreigh C, Solomons K. The influence of selective serotonin reuptake inhibitors on human platelet serotonin. Thromb Haemost 2004; 91: 119-128.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 5 McCloskey DJ, Postolache TT, Vittone BJ. et al. Selective serotonin reuptake inhibitors: measurement of effect on platelet function. Transl Res 2008; 151: 168-172.
    CrossrefPubMedGoogle Scholar
  • 6 Serebruany VL, Gurbel PA, O’Connor CM. Platelet inhibition by sertraline and N-desmethylsertraline: a possible missing link between depression, coronary events, and mortality benefits of selective serotonin reuptake inhibitors. Pharmacol Res 2001; 43: 453-462.
    CrossrefPubMedGoogle Scholar
  • 7 Li N, Wallen NH, Ladjevardi M. et al. Effects of serotonin on platelet activation in whole blood. Blood Coagul Fibrinolysis 1997; 8: 517-523.
    CrossrefPubMedGoogle Scholar
  • 8 Bevan J, Heptinstall S. Serotonin-induced platelet aggregation in whole blood and the effects of ketanserin and mepyramine. Thromb Res 1985; 38: 189-194.
    CrossrefPubMedGoogle Scholar
  • 9 De Clerck FF, Janssen PA. Amplification mechanisms in platelet activation and arterial thrombosis. J Hypertens Suppl 1990; 8: S87-93.
    PubMedGoogle Scholar
  • 10 Galan AM, Lopez-Vilchez I, Diaz-Ricart M. et al. Serotonergic mechanisms enhance platelet-mediated thrombogenicity. Thromb Haemost 2009; 102: 511-519.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 11 Opatrny L, Delaney JA, Suissa S. Gastro-intestinal haemorrhage risks of selective serotonin receptor antagonist therapy: a new look. Br J Clin Pharmacol 2008; 66: 76-81.
    CrossrefPubMedGoogle Scholar
  • 12 Dalton SO, Johansen C, Mellemkjaer L. et al. Use of selective serotonin reuptake inhibitors and risk of upper gastrointestinal tract bleeding: a population-based cohort study. Arch Intern Med 2003; 163: 59-64.
    CrossrefPubMedGoogle Scholar
  • 13 Gartner R, Cronin-Fenton D, Hundborg HH. et al. Use of selective serotonin reuptake inhibitors and risk of re-operation due to post-surgical bleeding in breast cancer patients: a Danish population-based cohort study. BMC Surg 2010; 10: 3.
    CrossrefPubMedGoogle Scholar
  • 14 Sauer WH, Berlin JA, Kimmel SE. Selective serotonin reuptake inhibitors and myocardial infarction. Circulation 2001; 104: 1894-1898.
    CrossrefPubMedGoogle Scholar
  • 15 Tata LJ, West J, Smith C. et al. General population based study of the impact of tricyclic and selective serotonin reuptake inhibitor antidepressants on the risk of acute myocardial infarction. Heart 2005; 91: 465-471.
    CrossrefPubMedGoogle Scholar
  • 16 Blanchette CM, Simoni-Wastila L, Zuckerman IH. et al. A secondary analysis of a duration response association between selective serotonin reuptake inhibitor use and the risk of acute myocardial infarction in the aging population. Ann Epidemiol 2008; 18: 316-321.
    CrossrefPubMedGoogle Scholar
  • 17 Carneiro AM, Cook EH, Murphy DL. et al. Interactions between integrin alphaIIbbeta3 and the serotonin transporter regulate serotonin transport and platelet aggregation in mice and humans. J Clin Invest 2008; 118: 1544-1552.
    CrossrefPubMedGoogle Scholar
  • 18 Dilks JR, Flaumenhaft R. Fluoxetine (Prozac) augments platelet activation mediated through pro-tease-activated receptors. J Thromb Haemost 2008; 6: 705-708.
    CrossrefPubMedGoogle Scholar
  • 19 Harper CM, Fukodome T, Engel AG. Treatment of slow-channel congenital myasthenic syndrome with fluoxetine. Neurology 2003; 60: 1710-1713.
    CrossrefPubMedGoogle Scholar
  • 20 Toth O, Calatzis A, Penz S. et al. Multiple electrode aggregometry: a new device to measure platelet aggregation in whole blood. Thromb Haemost 2006; 96: 781-788.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 21 Walther DJ, Peter JU, Winter S. et al. Serotonylation of small GTPases is a signal transduction pathway that triggers platelet alpha-granule release. Cell 2003; 115: 851-862.
    CrossrefPubMedGoogle Scholar
  • 22 De Clerck F, Xhonneux B, Leysen J. et al. Evidence for functional 5-HT2 receptor sites on human blood platelets. Biochem Pharmacol 1984; 33: 2807-2811.
    CrossrefPubMedGoogle Scholar
  • 23 Knight AR, Misra A, Quirk K. et al. Pharmacological characterisation of the agonist radioligand binding site of 5-HT(2A), 5-HT(2B) and 5-HT(2C) receptors. Naunyn Schmiedebergs Arch Pharmacol 2004; 370: 114-123.
    PubMedGoogle Scholar
  • 24 Glusa E, Markwardt F. Inhibition of 5-hydroxytryptamine-potentiated aggregation of human blood platelets by 5-hydroxytryptamine receptor-blocking agents. Biomed Biochim Acta 1984; 43: 215-220.
    PubMedGoogle Scholar
  • 25 Bevan J, Heptinstall S. Effects of combinations of 5-hydroxytryptamine receptor antagonists on 5-HT-induced human platelet aggregation. Naunyn Schmiedebergs Arch Pharmacol 1986; 334: 341-345.
    CrossrefPubMedGoogle Scholar